Your browser doesn't support javascript.
loading
Personalized radioiodine therapy for thyroid cancer patients with known disease.
Jhiang, Sissy M; Cheng, Peng; Nabhan, Fadi A; Sipos, Jennifer A; Menq, Chia-Hsiang.
Afiliación
  • Jhiang SM; Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210, USA.
  • Cheng P; Division of Endocrinology and Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
  • Nabhan FA; Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH 43210, USA.
  • Sipos JA; Division of Endocrinology and Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
  • Menq CH; Division of Endocrinology and Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Fac Rev ; 10: 36, 2021.
Article en En | MEDLINE | ID: mdl-33977289
ABSTRACT
Radioactive iodine (RAI) 131I is a targeted therapy for patients with RAI-avid follicular cell-derived thyroid cancer. However, the responsiveness to 131I therapy varies among thyroid cancer patients mainly owing to differential RAI uptake and RAI radiosensitivity among patients' lesions. A personalized approach to maximize 131I therapeutic efficacy is proposed based on recent scientific advances and future opportunities.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Fac Rev Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Fac Rev Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos